Clarithromycin is a 14-member lactone ring macrolide with potent activity against Haemophilus influenzae, including ampicillin-resistant strains. We evaluated the in vivo efficacy of clarithromycin at 40 mg/day and 100 mg/day for 3 days in the treatment of a murine model of pneumonia using a macrolide-resistant H. influenzae strain, which was also ampicillin resistant. The MIC of clarithromicin was 64 µg/ml. The viable bacterial counts in infected tissues after treatment with 100 mg/kg clarithromycin were lower than the counts obtained in control and 40 mg/kg clarithromycin-treated mice. Concentrations of macrophage inflammatory protein (MIP)-2 and interleukin (IL)-1 in bronchoalveolar lavage fluid (BALF) samples of mice treated at both concentrations were lower than in the control group. Pathologically, following infection, clarithromycin-treated mice, particularly at a dose of 100 mg/kg, showed lower numbers of neutrophils in alveolar walls, and inflammatory changes had apparently improved, whereas large aggregates of inflammatory cells were observed within alveoli of control mice. In addition, we demonstrated that clarithromycin has bacteriological effects against intracellular bacteria at levels below the MIC. Our results indicate that clarithromycin may be useful in vivo for macrolide-resistant H. influenzae, and this phenomenon may related the good penetration of clarithromycin into bronchoepitherial cells. We also believe that conventional drug susceptibility tests may not reflect the in vivo effects of clarithromycin.
INTRODUCTION
classified according to CLSI AMP susceptibility criteria: susceptible strain (AMP minimum inhibitory concentration (MIC) 1 µg/ml), intermediate strain (AMP MIC=2 µg/ml), and resistant strain (AMP MIC4 µg/ml).
Antibiotic examination
At 24 h after challenge with H. influenzae, CAMwas administered orally twice a day. Individual doses were either 40 mg/kg or 100 mg/kg, and treatment was administered for 3 days. Each group of mice was killed by cervical dislocation at 12 h after the final drug administration.
Bacteriological examination and BALF analysis was performed using the methods described above.
Three-hour invasion assay with NCI-H292 cells
The NCI-H292 epithelial cell line was obtained from the American Type Culture Collection (Manassas, VA). Cells were cultured in RPMI 1640 medium with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. Cells were grown at 37°C under 5% CO 2 in fully humidified air and were subcultured twice weekly. Cells were seeded in a 12-well plate at 5 × fetal bovine serum for 24 h. Cells were then rinsed with serum-free RPMI 1640 medium and exposed to bacteria. Bacterial suspensions at about 6×10 6 CFU/ml were inoculated at 10 μl/well.
Invasion assay was performed as reported previously (17, 32) . Briefly, cell monolayers were infected and incubated at 37°C under 5% CO 2 for 3 h, washed 3 times with phosphate buffer solution (PBS), and treated with gentamicin (Sigma, Tokyo, Japan) at a concentration of 200 μg/ml for 2 h in order to kill extracellular bacteria. CAM at concentrations below the MIC (2 µg/ml to 64 µg/ml) was mixed with gentamicin. Cell monolayers were washed 3 additional times with PBS, and viable intracellular bacteria were released by incubation with 0.5 ml of 1%
Triton X-100 (Sigma-Aldrich) in PBS for 15 min. Samples were harvested and vortex agitated for 1 min in order to lyse cells. Viable bacteria were serially diluted and plated onto chocolate agar (Nissui, Tokyo, Japan) for colony counting.
Statistical analysis
Data are expressed as means ± standard error of the mean (SEM). Differences between the numbers of viable bacteria in the lungs were evaluated by analysis of variance. Values of P<0.05 were considered to be statistically significant.
RESULTS

In vitro susceptibility
For H. influenzae clinical strain 4437, the MIC of CAM was 64 µg/ml. This strain was a BLNAR strain, and the AMP MIC was 16 µg/ml.
Changes in viable bacterial numbers over time (Figure1)
Respiratory infection occurred in all intubated mice with inoculation. The number of viable bacteria increased to 6.0±1.2 (log 10 CFU/ml) 3 days after inoculation in the control group, and there were no significant differences between the control group and the 40 mg/kg treatment group (5.8±0.8 (log 10 CFU/ml)). Conversely, the number of viable bacteria decreased significantly in the 100 mg/kg treatment group (4.6.±1.0 (log 10 CFU/ml)). These results indicate that CAM has in vivo bacteriological effects against the macrolide-resistant strain, as determined by conventional in vitro drug susceptibility tests.
BALF analysis
Total cell counts ( Figure 2A ) and neutrophil counts ( Figure 2B ) were significantly lower in both the 40 mg/kg treatment group and 100 mg/kg treatment group, particularly in the 100 mg/kg treatment group. To estimate further effects of CAM, inflammatory cytokine levels in BALF were analyzed. IL-1 ( Figure 3A ) and MIP-2 ( Figure 3B ) were significantly decreased in both treatment groups, particularly in the 100 mg/kg treatment group. These data indicate that CAM has dose-dependent anti-inflammatory effects against the acute inflammation induced by macrolide-resistant H. influenzae.
Histopathological examination
In non-treated mice, bronchioles and adjacent alveoli were filled with neutrophils, epithelial cells and inflammatory cells ( Figure 4A ). Conversely, in treated mice, although mild inflammatory changes were evident in the 40 mg/kg treatment group ( Figure 4B ), inflammation had improved after 3 treatment days, particularly in the 100 mg/kg treatment group ( Figure 4C ).
Intracellular bacteriological effects at various CAM concentrations
In conventional drug susceptibility tests, such as the microdilution method, PK and PD are not reflected in the antimicrobial effects against the pathogen that has invaded the bronchoepithelial cells. We performed 3 h invasion assay to investigate the intracellular bacteriological effects of CAM against macrolide-resistant H. influenzae, which was determined to be a highly resistant strain based on the CLSI judgment criteria. The number of intracellular H. influenzae in the control group (non-treatment group) was 4.8±1.2 (log 10 CFU/ml). We hypothesized that CAM shows bacteriorogical effects against macrolide-resistant H. influenzae at concentrations below MIC, as CAM attains higher concentrations in lung tissue than in serum. As shown in Figure 5 , CAM reduced the number of viable bacteria at less than half the MIC. This data indicates that CAM can eradicate macrolide-resistant H. influenzae at levels below the MIC, and may be able to prevent persistent and recurrent infection by this pathogen. In addition, the difference between our results and conventional drug susceptibility test results may be due to the good penetration of CAM into bronchoepithelial cells.
DISCUSSION
Macrolides and beta-lactams are the most commonly prescribed antimicrobials to treat infection by H. influenzae. Antimicrobial resistance is a growing problem among H. influenzae. BLNAR was first observed in the 1980s (8, 21, 24) at very low frequency in United States (3, 9, 13), but has rapidly become more common to account for 25 to 30% of isolates in Japan and the other Asian countries (13, 28, 34) . As safe and well-tolerated antibiotics, macrolides play a key role in the treatment of community-acquired respiratory tract infections (RTIs) against not only beta-lactam-susceptible strains, but also resistant strains such as BLNAR. Their broad spectrum of activity against gram-positive, gram-negative and atypical pathogens, has led to the widespread use of macrolides for empiric treatment of RTIs.
CAM is a 14-member lactone ring macrolide antibiotic, and although its increased utility has been compromised by intrinsic and acquired resistance to CAM, treatment failures are uncommon. Generally, in vitro resistance is based on the results of using susceptibility breakpoints developed by the CLSI. This susceptibility data is considered useful for determining epidemiological trends of resistance, but in vitro resistance is less useful for guiding clinical decisions, and does not necessarily indicate a lack of clinical efficacy.
The discrepancy may be based on the characteristic features of macrolides. It is known that macrolides are able to transfer and accumulate intracellularly, and show intracellular bactericidal effects. Moreover, macrolides are readily taken up by phagocytes, lymphocytes and epithelial cells (4, 30) . The concentration of macrolides in respiratory tract tissues and fluids has thus been shown to be higher than serum concentrations, resulting in the possibility of increased activity against organisms localized to these extra-plasma sites. The PD parameter of CAM has not yet been fully studied. CAM is considered concentration dependent by some investigators and concentration independent by others (5). Tessier et al (37) demonstrated AUC/MIC was the most reasonable predictor of CAM efficacy by using experimental S. pneumoniae pneumonia model. But they also showed that time above MIC and C max /MIC was also important parameter correlated with the change of bacterial load. In the present study, although we did not demonstrate which way is better 1 dose or twice a day in CAM administration, 100mg/kg treatment group showed improvement both in pathology and the inflammatory mediators, indicating that CAM may be able to show the dose, and concentration dependent efficacy against H. influenzae pneumonia.
Moreover, macrolides also have anti-inflammatory properties that improve clinical outcomes via extramicrobial mechanisms, leading to improvements in symptoms and overall quality of life among patients with a variety of respiratory conditions. None of these benefits are reflected by in vitro drug susceptibility testing.
Drug concentration of both in epithelial lining fluid (ELF) and alveolar macrophages (AM) is important to treat extracellular and intracellular bacteria. CAM is extensively concentrated in both ELF and respiratory phagocytes, reaching levels that are between one and three orders of magnitude higher than in plasma (2, 23) . Antibacterial potency is driven by the concentration of active agents at the site of infection, and thus in the case of macrolides, efficacy may be increased substantially by the tissue penetration described previously. This aspect of macrolide pharmacology is not taken into account by traditional drug susceptibility tests, such as the microdilution method. Thus, the most likely rationale is that in vitro resistance MICs are misleading, leading to underestimation of the clinical efficacy of these therapeutic agents.
In the present study, to investigate the differences between the in vivo effects and the results of It has been shown that antimicrobial drug therapy based on PK and PD is necessary for the treatment of infectious diseases (7). β-lactams, the most common antibiotics to treat respiratory infections, cannot eradicate bacteria that have invaded airway epithelial cells. Considering the pathology of airway infection by highly invasive H. influenzae strains, antimicrobial agents that readily penetrate airway epithelium to which bacteria show susceptibility is necessary. We performed cell invasive assay to estimate the effects of CAM against intracellular H. influenzae using a macrolide-resistant strain. Our data indicate that CAM can reduce intracellular viable bacterial number at concentrations lower than MIC, which was determined by the microdilution method. However, in this study, we did not measure intracellular CAM concentrations, and this effect may indicate intracellular concentrations higher than MIC, thus contributing to the good in vivo effects against H. influenzae, even in macrolide-resistant strains. Some authors were reported that CAM achieves high concentration not only in ELF but also intracellular space.
Rodvold et al. reported that the steady-state concentrations of CAM in ELF and AM obtained in intrapulmonary samples during bronchoscopy and bronchoalveolar lavage from 40 healthy of nonsmoking adult volunteers were analyzed, and CAM was extensively concentrated in ELF (34.4µg/ml at 4 h to 4.6µg/ml at 24 h) and AM (480µ/ml at 4 h to 99µg/ml at 24 h) (31).
However we did not measure the intracellular concentration of CAM in this time, our result may reflect the high penetration into the bronchial epithelial cell of CAM, from the viewpoint of PK.
We also consider that it may be useful information clinically because H. influenzae is known to invade into the respiratory epithelial cells and tend to escape the antibiotics effect.
Unfortunately, in vitro resistance data has a strong impact on the drug selection process, as macrolide therapy is largely empirical. This issue is not easy to resolve, as existing PD data use serum or plasma as an index for microbiological efficacy, which may not be appropriate for macrolides when they are used against organisms with higher MICs that reside in bodily fluids with drug concentration profiles that differ from those of serum. As time passes and more organisms become resistant, and therefore have higher MICs, this situation will become more confused, and one can predict that the macrolide class of antibiotics will probably be replaced by the ''respiratory'' quinolones for empirical therapy of respiratory tract infections. This may relegate the macrolides to the role of adjunctive agent in the treatment or prophylaxis of infections believed to be caused by intracellular pathogens. This would be unfortunate if it is based upon erroneous resistance data, and could deprive patients of an acceptable and somewhat unique (due to its high tissue penetration and immunological properties) class of agents; of course, the entire situation is further complicated by host immune function.
In conclusion, macrolide therapy remains a reasonable treatment for respiratory infection, even 
